Cardiovascular Benefits Across the BMI Spectrum The cardiovascular benefits of semaglutide were independent of baseline adiposity measures, meaning patients across the full spectrum of BMI values experienced similar relative risk reductions
In contrast, semaglutide 0.5 mg can be expected to reduce body weight by approximately 2 kg over 26 weeks
As Healio previously reported, in the STEP 1 study, published in The New England Journal of Medicine in February, adults with obesity assigned semaglutide 2.4 mg experienced substantial weight loss compared with placebo, with more than half of participants losing 15% of their body weight
"En pacientes con obesidad a quienes se les recet semaglutida o liraglutida, descubrimos que la reduccin de peso a largo plazo variaba significativamente segn el principio activo, la indicacin del tratamiento, la dosis y la persistencia con el medicamento", relata Hamlet Gasoyan, autor principal del estudio e investigador del Centro de Investigacin de Atencin Basada en el Valor de la Clnica Cleveland
It's important to have realistic expectations
If your vial has a different concentration, the conversion values here will not apply
